Research & Clinical Summary

The Saha Laboratory studies a highly lethal form of liver cancer called cholangiocarcinoma, or biliary tract cancer, which has been increasing in incidence worldwide for decades. We use a series of unique model systems that we have developed, including genetically engineered mouse models, patient-derived xenografts and cell lines to understand the fundamental pathogenic mechanisms of liver carcinogenesis and to identify new targeted therapies for specific genetic subsets of this disease. Our long-term goal is to transform the standard of care in cholangiocarcinoma from combination chemotherapy for all patients to ‘precision medicine’ with a specific targeted therapy regimen designed for each patient’s molecular profile.


More publications associated with this author on PubMed

The following publications were retrieved from PubMed:

2012Saha, Supriya

More publications associated with this author on PubMed